Text SizePrint

New NIH Study to Tackle Cardiovascular Heart Disease in HIV-infected Individuals

If you are HIV positive and on antiretroviral therapy (ART), are you doing all you can to maintain and improve your health?  While early diagnosis of HIV infection and use of combination ART has significantly reduced AIDS-related mortality and morbidity in the U.S., it does not completely return you to your pre-infection health status. For instance, studies have shown that HIV-infected individuals are at a higher risk (1.5-2 times) of developing cardiovascular disease (CVD). This higher risk may be linked to the consequences of the chronic immune activation and inflammation that persist in HIV-infected individuals on ART and which may contribute to metabolic disorders, such as lipodystrophy, atherosclerosis and subsequent cardiovascular events, such as heart attacks. The National Institutes of Health (NIH) is conducting a new study called REPRIEVE (A5332) to explore if the cholesterol-lowering statin drugs will also improve the health of HIV-infected individuals. To date, these medications have not been evaluated in HIV-infected individuals on HIV therapy.

The REPRIEVE (A5332) study, funded by the NIH’s National Heart Lung and Blood Institute with additional support from the National Institute of Infectious and Allergic Diseases, is a large efficacy study evaluating whether the statin medication, pitavastatin, can reduce the risk of CVD in HIV-infected adults who are taking ART. The study, which is being conducted by investigators from Harvard Medical School, Harvard School of Public Health and Duke University in collaboration with the NIH funded AIDS Clinical Trials Group, aims to enroll 6,500 HIV-infected adults between the ages of 40-75 years and who have been on any ART regimen for at least six months.  In addition, 800 study volunteers will also participate in a sub-study to examine the effects of pitavastatin on coronary artery disease and inflammatory biomarkers. If you would like to participate in the trial or would like more information on the REPRIEVE (A5332) study, please refer to Exit Disclaimer. A complete listing of the clinical trial’s sites and contact information can be found here: